title: Coenzyme Q10 plus Multivitamin Treatment Prevents Cisplatin Ototoxicity in Rats.
abstract: Cisplatin (Cpt) is known to induce a high level of oxidative stress, resulting in an increase of reactive oxygen species damaging the inner ear and causing hearing loss at high frequencies. Studies on animal models show that antioxidants may lower Cpt-induced ototoxicity. The aim of this study is to evaluate the ototoxic effects of two different protocols of Cpt administration in a Sprague-Dawley rat model, and to test in the same model the synergic protective effects of a solution of coenzyme Q10 terclatrate and Acuval 400®, a multivitamin supplement containing antioxidant agents and minerals (Acu-Qter). The Cpt was administered intraperitoneally in a single dose (14 mg/kg) or in three daily doses (4.6 mg/kg/day) to rats orally treated or untreated with Acu-Qter for 5 days. The auditory function was assessed by measuring auditory brainstem responses from 2 to 32 kHz at day 0 and 5 days after treatment. Similar hearing threshold and body weight alterations were observed in both Cpt administration protocols, but mortality reduced to zero when Cpt was administered in three daily doses. The Acu-Qter treatment was able to prevent and completely neutralize ototoxicity in rats treated with three daily Cpt doses, supporting the synergic protective effects of coenzyme Q terclatrate and Acuval 400® against Cpt-induced oxidative stress. The administration protocol involving three Cpt doses is more similar to common human chemotherapy protocols, therefore it appears more useful for long-term preclinical studies on ototoxicity prevention.
authors.affiliation: Bioacoustics Research Laboratory, Department of Neurosciences, University of Padua, Padua, Italy.|Foundation Onlus 'Staminali e Vita', Padua, Italy.
authors.forename: Laura
authors.initials: L
authors.lastname: Astolfi
authors.affiliation: Bioacoustics Research Laboratory, Department of Neurosciences, University of Padua, Padua, Italy.
authors.forename: Edi
authors.initials: E
authors.lastname: Simoni
authors.affiliation: Bioacoustics Research Laboratory, Department of Neurosciences, University of Padua, Padua, Italy.
authors.forename: Filippo
authors.initials: F
authors.lastname: Valente
authors.affiliation: ENT surgery - Department of Neurosciences, University of Padua, Padua, Italy.
authors.forename: Sara
authors.initials: S
authors.lastname: Ghiselli
authors.affiliation: Clinic of ENT, University of Ferrara, Ferrara, Italy.
authors.forename: Stavros
authors.initials: S
authors.lastname: Hatzopoulos
authors.affiliation: Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy.
authors.forename: Milvia
authors.initials: M
authors.lastname: Chicca
authors.affiliation: Bioacoustics Research Laboratory, Department of Neurosciences, University of Padua, Padua, Italy.|Foundation Onlus 'Staminali e Vita', Padua, Italy.|ENT surgery - Department of Neurosciences, University of Padua, Padua, Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Martini
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity*; D002945:Cisplatin / Q000633:toxicity*; D004334:Drug Administration Schedule; D007758:Ear, Inner / Q000187:drug effects*; D034381:Hearing Loss / Q000517:prevention & control; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D014451:Ubiquinone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D014815:Vitamins / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D014815:Vitamins; D014451:Ubiquinone; C024989:coenzyme Q10; D002945:Cisplatin